Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenosylhomocysteinase like 2 (AHCYL2) encodes a protein structurally related to S-adenosylhomocysteine hydrolases and may function in the reversible conversion of S-adenosyl-L-homocysteine to L-homocysteine and adenosine within the one-carbon metabolism pathway[2][3][8]. AHCYL2 is most notable for its homology to AHCYL1; however, unlike AHCYL1, it does not regulate ITPR1 sensitivity to inositol 1,4,5-trisphosphate but may modulate the activity of the sodium/bicarbonate cotransporter SLC4A4[3][5]. It is a homotetrameric protein, expressed in diverse human tissues, with several transcript variants encoding different isoforms[3][8][9]. Clinical associations have been observed with certain brain malformation syndromes and glycine N-methyltransferase deficiency, but it is not currently a recognized drug target and no specific drug interactions are documented[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosylhomocysteinase like 2 (AHCYL2).